Stocks
Cipla infringing Roche's patent in lung cancer drug: HC
In a setback to Cipla, the Delhi High Court on Friday held that the Indian drug major was infringing Swiss pharmaceutical company Hoffman-La Roche's patent in lung cancer drug erlotinib hydrochloride, sold under the name of Tarceva.
 
A division bench of Justice Pradeep Nandrajog and Justice Mukta Gupta held that Cipla's lung cancer medicine, Erlocip, was one polymorphic form of the compound, which may exist in several forms.
 
"This (the patent) is a sufficiently broad claim that is clearly not limited to any polymorphic version of erlotinib hydrochloride, but to erlotinib hydrochloride itself. This compound may exist in several polymorphic forms, but any and all such forms will be subsumed within this patent. 
 
"Therefore as Cipla's Erlocip is admittedly one particular polymorphic form of the erlotinib hydrochloride compound (polymorph B), it will clearly infringe the IN 774 patent (of Roche)," said the court.
 
It added: "We thus conclude this issue by noting that the single judge's finding that 'Tarceva' and 'Erlocip' were based on the polymorph B version of erlotinib hydrochloride, though correct factually, is irrelevant to the subject matter of the present patent as Cipla has clearly infringed Claim 1 of Roche's IN 774 patent in arriving at the said polymorph." 
 
The court's order came on the pleas of Cipla and Roche, both of which had challenged the September 7, 2012 order of a single judge, who had held that Cipla was not infringing Roche's patent and refused to grant any injunction against the Indian company. 
 
Disclaimer: Information, facts or opinions expressed in this news article are presented as sourced from IANS and do not reflect views of Moneylife and hence Moneylife is not responsible or liable for the same. As a source and news provider, IANS is responsible for accuracy, completeness, suitability and validity of any information in this article.

User

How jogging helps you stay sharp
Exercise can enhance the development of new brain cells that play an important role in learning and memory of adults, new research has found.
 
The process of developing new brain cells in the adult brain is called adult neurogenesis, the scientists explained.
 
The researchers found that mice that spent time running on wheels not only developed twice the normal number of new neurons, but also showed an increased ability to distinguish new objects from familiar objects. 
 
"Our research indicates that exercise-induced increase in neurogenesis improves pattern separation by supporting unique and detailed long-term representations of similar but nevertheless different memory items,” explained lead investigator Josef Bischofberger, professor at University of Basel in Switzerland.
 
“Pattern separation is involved in many memory tasks of everyday life. For example, when learning the game of chess, it is critically important to remember the different shapes of pieces like the pawn and bishop,” Bischofberger explained.
 
For the study, the researchers tested two groups of mice that were housed either without (sedentary) or with running wheels (voluntarily running) using a novel object recognition task to assess learning and long-term memory. 
 
The researchers found that whereas distinct objects were remembered and recognized by both cohorts of mice, only the running mice could faithfully distinguish similar looking objects. 
 
Investigators determined therefore that the running mice had developed better pattern separation capabilities than sedentary mice.
 
To investigate further, the researchers looked for changes in the brains of the mice. By using markers that could identify newly-formed brain cells, they found that running mice developed about twice as many new cells.
 
The study was published in the journal of Brain Plasticity.
 
Disclaimer: Information, facts or opinions expressed in this news article are presented as sourced from IANS and do not reflect views of Moneylife and hence Moneylife is not responsible or liable for the same. As a source and news provider, IANS is responsible for accuracy, completeness, suitability and validity of any information in this article.

User

Delhi's Jan Lokpal to have power to probe central officials
The central and Delhi governments may be headed for a showdown with the AAP's Jan Lokpal bill giving the proposed ombudsman the power to probe even central government officials.
 
According to the Delhi Jan Lokpal Bill 2015, a copy of which is in the possession of IANS, the Jan Lokpal may proceed to inquire or investigate into the allegation of "corruption" occurring in the national capital territory of Delhi" and a Delhi minister held this meant any central government functionary.
 
Tourism Minister Kapil Mishra told IANS that Lokpal will have the power to investigate the prime minister if he committed corruption in Delhi.
 
"The Jan Lokpal proposed by us will be able to probe against anyone who has done corruption in the national capital. It does not matter whether he is central government official or state government official," Mishra told IANS.
 
A source said that the bill is likely to be tabled in the Delhi assembly on Monday.
 
Other measures of the proposed bill include the chief minister also coming under the purview of the ombudsman. However, for filing false complaints with Jan Lokpal, there will be "rigorous imprisonment which may extend to one year or with fine which may extend to Rs.1 lakh or with both".
 
The panel responsible for selecting Jan Lokpal will consist of the Delhi High Court's chief justice, Delhi chief minister, leader of opposition in Delhi assembly and the speaker.
 
The bill says that the lt. governor will appoint a three-member body having a chairperson and two members to be known as the Jan Lokpal.
 
The ombudsman will have a five-year term.
 
The bill also says that Jan Lokpal may, for the purpose of conducting any inquiry or investigation, utilise the services of any officer or organisation or investigation agency of the central government or any other state or union territory governments. The probe has to be completed within six months.
 
Disclaimer: Information, facts or opinions expressed in this news article are presented as sourced from IANS and do not reflect views of Moneylife and hence Moneylife is not responsible or liable for the same. As a source and news provider, IANS is responsible for accuracy, completeness, suitability and validity of any information in this article.

User

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)